Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
NNNN
Anbio Biotechnology
CAPPED RATING
Anbio Biotechnology (NNNN) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A-); its weakest is Momentum (F).
Quantitative Factor Evaluation • Updated
Overall Rating
2.8
/ 5.0
C+
Value
B-
Factor Score
3.0
/ 5.0
Growth
A-
Factor Score
4.1
/ 5.0
Profitability
B+
Factor Score
3.8
/ 5.0
Momentum
F
Factor Score
0.7
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
25.3
EV / EBITDA
N/A
Rev Growth YoY
73.9%
Gross Margin
87.2%
Price Return 3M
-56.5%
Price Return 12M
-83.6%
Catalyst Signal
0.00
Market Cap
$166.8M
TTM Revenue
$8.6M
Price / Sales
19.3
ROE
27.0%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | A- (4.1) | B+ (3.8) | F (0.7) | C+ (2.6) | C+ (2.8) |
| 2026-11-06 | B- (3.0) | A (4.3) | B+ (3.8) | F (0.6) | C+ (2.7) | B- (2.9) |
| 2026-10-30 | B- (3.0) | A (4.2) | B+ (3.8) | F (0.6) | C+ (2.7) | B- (2.9) |
| 2026-10-23 | B- (3.0) | A (4.2) | B+ (3.8) | F (0.6) | C+ (2.6) | C+ (2.8) |
| 2026-10-16 | B- (3.0) | A (4.2) | B+ (3.8) | F (0.6) | C+ (2.6) | C+ (2.8) |
Page
1
of
4